Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jul 22, 2021 11:34am
162 Views
Post# 33587771

RE:Yesterday's big volume on the TSX

RE:Yesterday's big volume on the TSX

It's almost like they've now remembered to do what they forgot to do for the past 2 years.

Having said that though it definitely feels like we are reaching a turning point. You identified the company going through a transition, with all the changes Paul is implimenting it feels almost like a re-structuring. Maybe that's over-stating things. With clarity on the R&D assets and Paul implementing his changes it feels like we are reaching the end of that process.

I'm not sure selling the re-structuring process is as easy or profitable as selling what comes out of it.


SPCEO1 wrote: I suspect the reason we saw big volume yesterday on the TSX (beating the volume on NASDAQ for the first time in recent memory) is because TH was likely speaking with analysts and portfolio managers in Canada the last couple of days and now is moving to the US via Cantor. Whenever they put out a new corporate presentation, you pretty much know they are starting an analyst/PM tour. 

Given that TH has now sorted out its strategy re: cancer and NASH, an analyst/PM tour makes sense to explain that. Apparently, they got at least one or two Canadian institutions they visited with to buy, which is good. Hopefully, they have even better success in the US. And even more hopefully, they will get the Cantor analyst to pick up coverage on them. If some of Cantor's clients are intrigued by what they hear today, that will certainly increase the odds of Cantor picking up coverage, but those odds are likely still not fantastic.   



 

<< Previous
Bullboard Posts
Next >>